TELIF Overview

Debt Settlement Announcement: Telescope Innovations Corp. has agreed to settle CAD $100,000 in outstanding indebtedness by issuing 689,654 common shares, including 344,827 shares to Chief Technology Officer Jason Hein.

Loan Facility Details: The company has a secured loan facility of CAD $1,200,000 with a 6.95% interest rate, maturing on June 1, 2026, and will also settle CAD $100,000 of this loan through the issuance of shares.

Related Party Transaction: The issuance of shares to Jason Hein is classified as a related party transaction under Multilateral Instrument 61-101, with the company relying on exemptions from formal valuation and minority shareholder approval.

Forward-Looking Information Disclaimer: The news release includes forward-looking information, which is subject to risks and uncertainties, and the company disclaims any obligation to update such information unless required by law.

Loan Agreement Announcement: Telescope Innovations Corp. has secured a CAD $1,200,000 loan from a group of lenders, including its directors Jason Hein and Henry Dubina, to support operational activities, with a maturity date of June 1, 2026.

Technology Development Focus: The company is advancing its Self Driving Laboratory (SDL) platforms that integrate robotics and AI to enhance chemical process development, positioning itself strategically as pharmaceutical companies seek modernization amidst market uncertainties.

Financial Performance: Telescope Innovations Corp reported Q2 fiscal results with revenues of CAD 1.0 million and an adjusted EBITA loss of CAD 0.4 million, while strategically reinvesting to drive growth.

Operational Developments: The company expanded its flagship product into China, launched a new accessory for its DirectInject-LC™ product, and made significant progress in collaboration with Pfizer on self-driving lab technology, alongside successful outcomes in producing battery-grade lithium carbonate.

Virtual Investor Forum Availability: Presentations from the Life Science Virtual Investor Forum held on March 13 are now available for online viewing for 90 days, allowing investors to access company materials and schedule one-on-one meetings until March 18.

About Virtual Investor Conferences: Virtual Investor Conferences (VIC) is a leading platform that facilitates direct presentations from publicly traded companies to investors, enhancing engagement through interactive features and targeted meeting scheduling.

Event Announcement: The Life Sciences Investor Forum, co-hosted by Zacks Small Cap Research, will take place on March 13, 2025, offering a platform for individual and institutional investors to engage with life sciences companies through live presentations and one-on-one meetings.

Participation Details: Investors are encouraged to pre-register for the event at no cost, ensuring they can efficiently participate and receive updates about the conference.

Event Announcement: Telescope Innovations Corporation will present at the Virtual Life Science Investor Forum on March 13, 2025, with live Q&A opportunities for investors and an archived webcast available afterward.

Company Highlights: Recent achievements include a collaborative research agreement with Pfizer, global distribution partnership with Mettler Toledo, and recognition of its founder with the R. U. Lemieux Award.